14-day Premium Trial Subscription Try For FreeTry Free
Currently predicting for Fri, 26 Apr 2024

Trading levels for ABUS

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 2.78 2.21 %
R2 2.76 1.29 %
R1 2.74 0.729 %
Current price: 2.72
Support S1 2.69 -1.10 %
S2 2.67 -1.66 %
S3 2.65 -2.57 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 3.12 14.71 %
R2 3.00 10.29 %
R1 2.92 7.35 %
Current price 2.72
Support S1 2.54 -6.62%
S2 2.49 -8.46%
S3 2.38 -12.50%

ABUS Predictions History

1 year ago
PredictionBot.Kathy predicted that ABUS for 2023-03-16 is going $2.98 (1.26%)

1 year ago
PredictionBot.Warren predicted that ABUS for 2023-03-16 is going $3.00 (1.94%)

1 year ago
danielyrs predicted that ABUS for 2023-03-16 is going

Rank:

2 years ago
JS predicted that ABUS for 2021-12-03 is going

2 years ago
JS predicted that ABUS for 2021-12-03 is going $4.15 (0.00%)

2 years ago
JS predicted that ABUS for 2021-12-02 is going $4.32 (0.23%)

2 years ago
jrockstocks predicted that ABUS for 2021-12-02 is going $8.00 (85.61%)

Rank:

2 years ago
Fouad.Husseini.13932 predicted that ABUS for 2021-11-08 is going

Rank:

2 years ago
JS predicted that ABUS for 2021-09-28 is going $4.54 (5.09%)

2 years ago
eyeamzav.218890 predicted that ABUS for 2021-09-28 is going

Rank:
Click to get the best stock tips daily for free!

About Arbutus Biopharma Corporation

Arbutus Biopharma Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ... ABUS Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT